Navigation Links
Drug combination shrinks breast cancer metastases in brain
Date:12/17/2007

SAN ANTONIO, Texas--A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.

Lapatinib (Tykerb) and capecitabine (Xeloda) were paired in an extension of a Phase 2 clinical trial in which lapatinib given alone shrank brain metastases significantly in six percent of 241 patients.

In the extension trial, capecitabine was added to lapatinib in 49 patients whose metastases -- cancerous colonies in the brain spread from their primary cancer -- had progressed while on treatment. With the combination therapy, brain metastases shrank by 20 percent or more in 18 patients (37 percent) and shrank by at least 50 percent in 10 patients (20 percent), reported Nancy Lin, MD, of Dana-Farber's Breast Oncology Center.

"Very few medications have shown activity in the treatment of brain metastases, particularly in HER-2-positive metastatic breast cancer patients," said Lin, who led the study with Eric Winer, MD, director of the Dana-Farber Breast Oncology Center. "Therefore, these data are quite encouraging, and further studies are warranted."

The data (abstract 6076) will be presented on Sunday, Dec. 16 at 7 a.m. CT.

Lapatinib is an oral small-molecule drug from GlaxoSmithKline that is approved along with capecitabine for treating patients with advanced or metastatic breast cancer whose tumors are driven by the abnormal growth signal, HER-2, and who have already undergone therapy including trastuzumab (Herceptin), a taxane drug, and an anthracycline compound. Lapatinib, like trastuzumab, blocks the HER-2 signal.

Up to one-third of women with advanced, HER-2-positive breast cancer may develop metastases to the brain.

"Although radiation treatment is often effective, as women live longer with metastatic cancer, some develop worsening of brain metastases despite radiation," said Lin. "Because cancer in the brain can have a major impact on quality of life, it is important to have treatment options to address this problem."


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... NutraPre today announced the ... pregnant women to prevent morning sickness and promote overall heath. Engineered with advanced ... and taste of water. , “Imagine a pregnancy without morning sickness,” NutraPre CEO ...
(Date:5/23/2016)... Angeles, CA (PRWEB) , ... May 23, 2016 , ... ... surgeons have noted that, less than 1% of United Kingdom residents who could benefit ... UK’s National Health Service (NHS) increases the number of bariatric procedures it offers to ...
(Date:5/23/2016)... ... , ... NYDNRehab, a New York City-based physical therapy clinic , is ... this type of technology, which was developed by world-renowned researcher Dr. Christopher Powers of ... , With over 10 million sport injuries per year in the United ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Society for Women’s Health ... to move on from that role. , “No one in Washington led the way ... said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep gratitude to Phyllis ...
(Date:5/23/2016)... , ... May 23, 2016 , ... ... care to residents of Westchester County for over 24 years, recently hosted its ... community members joined HOW for two remembrance ceremonies, each concluding with the release ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... 2016 - Revenue Forecasts ... Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine ... New Study Reveals Selling Opportunities and Revenue Prospects ... ,What is the future of biologics, especially new ... commercial analysis. Staying ahead in data and knowledge, ...
(Date:5/19/2016)... Calif. , May 19, 2016  According ... thirds of the world lacks basic diagnostic imaging. ... in the United States , ... to such technology. In fact, the WHO reports ... risk of avoidable or treatable death, simply due ...
(Date:5/19/2016)... According to a new market research report "Sunitinib Malate ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected to ... from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... through 26 Pages and in-depth TOC on "Sunitinib Malate ...
Breaking Medicine Technology: